Simon Quick Advisors LLC Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Simon Quick Advisors LLC cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,018 shares of the biopharmaceutical company’s stock after selling 39 shares during the quarter. Simon Quick Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $725,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $26,000. Fairfield Financial Advisors LTD acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $37,000. Truvestments Capital LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $39,000. Finally, Valley Wealth Managers Inc. acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $49,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on REGN shares. JPMorgan Chase & Co. dropped their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Morgan Stanley decreased their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Barclays dropped their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, Evercore ISI reduced their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Trading Down 1.1 %

Shares of Regeneron Pharmaceuticals stock opened at $680.03 on Thursday. The firm has a 50-day simple moving average of $733.06 and a two-hundred day simple moving average of $943.95. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $666.25 and a fifty-two week high of $1,211.20. The company has a market cap of $74.73 billion, a P/E ratio of 16.83, a price-to-earnings-growth ratio of 1.61 and a beta of 0.10.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.